XRCC1单核苷酸多态性与鼻咽癌放疗近期 疗效的相关性分析

目的 探讨XRCC1单核苷酸多态性与鼻咽癌放疗敏感性的关联性。 方法 放疗前采鼻咽癌患者静脉血,用多聚链酶反应-高温连接酶反应(PCR-LDR)进行XRCC1Arg399Gln基因的分型,观察各型放疗中及放疗后3个月的疗效。结果 放疗中期Gln/Gln基因型的肿瘤退缩率为0.855±0.026,显著高于Arg/Gln基因型的0.386±0.183和Arg/Arg基因型的0.377±0.169,差异有统计学意义( F =11.16, P =0.0003);XRCC1 Codon399Gln/Gln型放疗后3个月CR达100%,Arg/Gln型为76.2%,Arg/Arg型为66.7%,三者差异无统计学意义。结论 XRCC1Codon399基因型可以预测鼻咽癌放疗中期的局部疗效。

Relationship between polymorphisms of XRCC1 and the short-term effect of radiotherapy of nasopharygeal carcinoma

Objective To find the intrinsic influencing factor of radiosensitivity, and to detect the polymorphisms of XRCC1 of the patients suffering from nasopharygeal carcinoma(NPC) and the different short-term curative effect of radiotherapy. Methods XRCC1 Codon Arg399Gln was determined by polymerase chain reaction and ligase detection reaction(PCR-LDR), and the effect of radiotherapy of NPC on mid-therapy and 3 months after finishing radiation were observed. Results On mid-radiotherapy, the retraction rate of Gln/Gln genotype was 0.855±0.026, which was higher than that of Arg/Gln (0.386±0.183) and Arg/Arg genotypes (0.377±0.169) ( F = 11.16, P = 0.0003). The CR rate of 3 months after radiotherapy of the case with Gln/Gln was 100%, Arg/Gln was 76.2%, Arg/Arg was 66.7% ( P >0.05). Conclusion Polymorphisms of XRCC1Arg399Gln could be a predictor for the radiotherapy effect of NPC on mid-radiotherapy.